Cover
Cover | 12 Months Ended |
Dec. 31, 2022 shares | |
Entity Addresses [Line Items] | |
Document Type | 20-F/A |
Amendment Flag | true |
Amendment Description | Biodexa Pharmaceuticals PLC (the “Company”) is filing this Amendment No. 1 (the “Amendment”) on Form 20-F/A to amend its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2023 (the “Original Filing”), to replace the Report of Independent Registered Public Accounting Firm (the “Auditor's Report”) included in the Original Filing to include narrative regarding the Critical Audit Matter that was disclosed in respect of the Company’s ability to continue as a going concern, including one of the related procedures performed, that were inadvertently excluded from such Auditor Report, along with other minor changes that do not affect the opinion included in such Auditor Report. This Amendment also includes an updated consent of the Company’s independent registered public accounting firm. As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, a certification by the Company’s principal executive officer and principal financial officer is filed as an exhibit to the Amendment under Item 19 of Part III hereof. Paragraphs 3, 4 and 5 of this certification have been omitted in accordance with the SEC’s rules and guidance. Additionally, the Amendment does not include the certifications under Section 906 of the Sarbanes-Oxley Act of 2002, as no financial statements are being filed with the Amendment. Except as described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the dates described in the Original Filing, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to such dates. Accordingly, this Amendment should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Filing, as information in such filings may update or supersede certain information contained in this Amendment. |
Document Registration Statement | false |
Document Annual Report | true |
Document Transition Report | false |
Document Shell Company Report | false |
Document Period End Date | Dec. 31, 2022 |
Document Fiscal Period Focus | FY |
Document Fiscal Year Focus | 2022 |
Current Fiscal Year End Date | --12-31 |
Entity File Number | 001-37652 |
Entity Registrant Name | BIODEXA PHARMACEUTICALS PLC |
Entity Central Index Key | 0001643918 |
Entity Incorporation, State or Country Code | D5 |
Entity Address, Address Line One | 1 Caspian Point |
Entity Address, Address Line Two | Caspian Way |
Entity Address, City or Town | Cardiff |
Entity Address, Country | GB |
Entity Address, Postal Zip Code | CF10 4DQ |
Title of 12(b) Security | American Depositary Shares, each representing five ordinary shares |
Trading Symbol | BDRX |
Security Exchange Name | NASDAQ |
Entity Well-known Seasoned Issuer | No |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Non-accelerated Filer |
Entity Emerging Growth Company | false |
Document Accounting Standard | International Financial Reporting Standards |
Entity Shell Company | false |
Entity Common Stock, Shares Outstanding | 5,417,137 |
Auditor Name | Mazars LLP |
Auditor Location | London, England |
Auditor Firm ID | 338 |
Business Contact [Member] | |
Entity Addresses [Line Items] | |
Entity Address, Address Line One | 1 Caspian Point |
Entity Address, Address Line Two | Caspian Way |
Entity Address, City or Town | Cardiff |
Entity Address, Country | GB |
Entity Address, Postal Zip Code | CF10 4DQ |
Country Region | +44 |
City Area Code | 29 |
Local Phone Number | 2048 0180 |
Contact Personnel Name | Stephen Stamp |